Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FANCA
REST API REST API
Homo sapiens
FANCA is differentially expressed in 310 experiments: 118 organism parts: bone marrow, skeletal muscle, ... (116 more);, 214 disease states: normal, cervical carcinoma, ... (212 more);, 105 cell types 412 cell lines 39 compound treatments and 86 other conditions.
Synonyms FACA, FA-H, FANCH, FAH, FAA
Orthologs FANCA (Gallus gallus)   FANCA (Danio rerio)   FANCA (Bos taurus)   Fanca (Mus musculus)   Fanca (Rattus norvegicus)   FANCA (Xenopus laevis)   FANCA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, DNA repair, cytoplasm, regulation of cell proliferation, male gonad development, protein complex assembly, female gonad development, nucleus, nucleoplasm, male meiosis, Fanconi anaemia nuclear complex
InterPro Term Fanconia
UniProt Accession O15360, Q0VAP4, F5H8D5, B7Z6Y4
Gene-Disease Assocation FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
Search EB-eye ENSG00000187741
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (46 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
Jurkat
2
E-GEOD-1880, E-MEXP-2197
NCI-H929
2
E-MEXP-1269, E-MTAB-62
HCC1954
2
E-GEOD-29119, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
HT1080
2
E-MTAB-37, E-GEOD-20089
406 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (53 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-TABM-145, E-AFMX-5
memory B cell
2
E-MEXP-2360, E-TABM-702
stromal cell
2
E-GEOD-10797, E-GEOD-1460
centroblast
2
E-TABM-702, E-GEOD-15271
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD56+ NK cells
1
E-AFMX-5
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-GEOD-2514, E-MTAB-62
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
208 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
none
4
5
E-TABM-782, E-GEOD-5824, E-GEOD-20719, E-MEXP-1230, E-MEXP-1958, ... (9 experiments)
hydroxyurea
1
E-GEOD-571
unknown
1
E-GEOD-7307
TNF
1
E-GEOD-15205
arsenic oxide
1
E-GEOD-6907
AMP
1
1
E-MEXP-2285
33 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
37
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-2034, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-3494, E-MEXP-421, E-GEOD-22593, E-GEOD-18005, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (43 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.457 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM